William Blair analyst Myles Minter has reiterated their bullish stance on XENE stock, giving a Buy rating on November 26.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Myles Minter has given his Buy rating due to a combination of factors surrounding Xenon’s promising developments in epilepsy treatment. The company presented compelling data at the American Epilepsy Society Annual Meeting, showcasing the sustained efficacy of their drug azetukalner in reducing seizures by over 90% in patients with focal onset seizure epilepsy over a 48-month period. This significant reduction in seizures is particularly noteworthy given the refractory nature of the patient population, who were already on multiple antiseizure medications.
Minter is optimistic about the future prospects of Xenon, especially with the upcoming results from the fully enrolled pivotal X-TOLE2 trial expected in early 2026. The potential for azetukalner to become a blockbuster drug due to its novel mechanism of action and differentiation in a crowded market is a key factor in the Buy rating. The anticipation of these trial results and the drug’s commercial potential are seen as major catalysts for the stock, reinforcing confidence in Xenon’s strategic direction and growth potential.
According to TipRanks, Minter is a 5-star analyst with an average return of 28.5% and a 61.25% success rate. Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Vertex Pharmaceuticals, and VistaGen Therapeutics.
In another report released on November 26, Wells Fargo also maintained a Buy rating on the stock with a $44.00 price target.